Cancer Registry Software Market size is estimated to reach $158 million by 2030; prevalence of cancer cases, the increase in research and development in the oncology sector government initiatives for cancer surveillance & need for improved cancer dat

Cancer Registry Software Market size is estimated to reach $158 million by 2030, growing at a CAGR of 10.7% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Cancer Registry Software Market- By Type (Stand-alone Software, Integrated Software), By Registry ( Integrated Software, Hospital-based Cancer Registry), By Deployment (On-Premise, On - Cloud), By Database Type (Commercial Database, Public Database), By Functionality (Patient Care, Cancer Reporting, Medical Research), By Pricing Model (Subscription-based, Per User Licensing, One Time Purchase) By End User (Government Organizations, Third-Party Administrators, Biotechnological and Medical Device Companies, Research Centres) By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030”

The cancer registry software market is growing rapidly due to an increase in a number of cancer cases around the world, resulting in a high demand for effective solutions in data management. In addition, the installation of advanced software systems is mandatory due to the stringent regulatory demands concerning cancer reporting and data collection. 

North America held the largest share of 37% in the Cancer Registry Software Market in 2023 due to its advanced technological penetration, and high prevalence of cancer cases. The region also has the highest healthcare spending. The Canadian Institute for Health Information (CIHI) reported that in 2023, Canada’s healthcare expenditure was roughly 11.5% of its GDP and the CIHI forecasts an increase of 3.5% in Canada’s healthcare expenditur in 2024. The region also has a high incidence of cancer, specifically, the U.S. According to the Association of Cancer Society, in 2023, a little over 1.9 million new cases of cancer are expected to be diagnosed in the United States The greatest number of deaths are from cancers of the lung, prostate and colorectum in men and cancers of the lung, breast and colorectum in women. 

The prevalence of cancer worldwide poses a significant public health challenge, affecting millions of individuals and families. According to the Union for International Cancer Control, IARC's 2022 report shows 20 million new cancer cases and 9.7 million deaths globally, with lung and breast cancers being the most common. According to the World Health Organisation, globally over 35 million new cancer cases are predicted in 2050. This alarming data underscores the urgent need for effective prevention and treatment strategies on a global scale. Additionally, disparities in cancer burden and mortality exist between high and low Human Development Index (HDI) countries. It is true that in most developed countries, there are good facilities that allow for early detection and timely intervention but in most low HDI countries, there are barriers that prevent meaningful engagement to this disease. Eliminating these inequalities is of paramount importance for cancer prognosis improvement.

Innovation in cancer therapy and management is being fuelled by increased research and development in the oncology field, which is also improving patient outcomes. 25 new active substances (NASs) for oncology were introduced globally in 2023, bringing the total to 193 since 2014. This increase is indicative of a rising dedication to using personalized medicine and tailored medicines to address the challenges of cancer. Nonetheless, there are significant regional differences in the accessibility of these medications, underscoring inequities in access to cutting-edge care. Certain regions gain more from these breakthroughs than others, particularly those with strong healthcare infrastructures. Sustained research and development expenditures are necessary to create novel treatments as well as to guarantee fair access, which will ultimately improve survival rates for a variety of groups and advance cancer care worldwide.

Key companies profiled in the Cancer Registry Software Market are Elekta, Oracle Corporation, Health Catalyst Inc, McKesson Corporation, C/NET Solutions, Q-Centrix, LLC, Conduent, Inc, ONCO, Inc., NeuralFrame, Inc., Varian Medical Systems, Inc, and others

Medical Imaging Software Market – The Medical Imaging Software Market size is analysed to reach $4.3 billion by 2027 and is poised to grow at a CAGR of 7.2% over the forecast period of 2022-2027. The increasing prevalence of various chronic diseases like cancer, arthritis, etc, are majorly responsible for the growing size of the medical imaging software market.

Oncology Market – Oncology Market size is valued at $136.7 billion in 2019 and is poised to grow at a CAGR of 11.9% during the forecast period 2020-2025. Increased prevalence of cancer, unhealthy lifestyle, and increasing geriatric population are the primary factors driving the growth of the Oncology Market. 

Cancer Testing Screening Market – Cancer Testing Screening Market Size is forecast to reach $267298 Million by 2030, at a 6.60% during forecast period 2024-2030. The improved research and development activities coupled with the increasing public awareness of cancer diseases are all predicted to create a new window of opportunities in the global cancer Testing screening market.